Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.40 |
| ▸ | TPH1 | P17752 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711681 | 1.00 | ALPI (0.44) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL1711366 | 0.82 | CTRB1 (0.45) | MMP8 | |
| SCHEMBL1711436 | 0.82 | CTRB1 (0.45) | MMP8 | |
| SCHEMBL28022070 | 0.81 | SLC7A5 (0.45) | SLC7A5 | |
| SCHEMBL1711607 | 0.81 | MMP8 (0.38) | MMP8 | |
| SCHEMBL1711440 | 0.81 | MMP8 (0.38) | MMP8 | |
| SCHEMBL11199554 | 0.77 | SLC7A5 (0.46) | SLC7A5MMP2 | |
| SCHEMBL9190966 | 0.76 | GNAI3 (0.37) | SMN1; SMN2MMP2 | |
| SCHEMBL9189322 | 0.76 | ALOX15 (0.41) | — | |
| SCHEMBL1711578 | 0.76 | SLC7A5 (0.39) | SLC7A5ANPEPRNPEPDNPEPMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052288-A1 | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-03-09 | — | — | US | claimed |
| US-20030092608-A1 | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | TANABE SEIYAKU CO., LTD. (JP) | 2003-05-15 | — | — | US | claimed |
| CN-100372570-C | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor | TANABE SEIYAKU CO (JP) | 2008-03-05 | — | — | CN | disclosed |
| US-20060052288-A1 | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-03-09 | — | — | US | disclosed |
| CN-1545423-A | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor | ������ҩ��ʽ���� | 2004-11-10 | — | — | CN | disclosed |
| EP-1418947-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYSACCHARIDE CONJUGATES FOR INHIBITING THE METASTASIS OR PREVENTING THE RECURRENCE OF MALIGNANT TUMOR | TANABE SEIYAKU CO., LTD. (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-20030092608-A1 | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | TANABE SEIYAKU CO., LTD. (JP) | 2003-05-15 | — | — | US | disclosed |
| WO-2003015826-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYSACCHARIDE CONJUGATES FOR INHIBITING THE METASTSIS OR PREVENTING THE RECURRENCE OF MALIGANT TUMOR | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092608-A1 | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | CD44, MUC1, HGFAC | ALPI 920/4885PKM 2086/4885PTGS1 349/4885 |
| US-20060052288-A1 | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | CD44, MUC1, HGFAC | ALPI 920/4885PKM 2086/4885PTGS1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.